

The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME

LUCA VANELLA¹, CLAUDIA DI GIACOMO¹, ROSARIA ACQUAVIVA¹, ROSA SANTANGELO¹,
VENERA CARDILE², IGNAZIO BARBAGALLO¹, NADER G. ABRAHAM³ and VALERIA SORRENTI¹

¹Dipartimento di Scienze del Farmaco, Sezione di Biochimica, ²Dipartimento di Scienze Fisiologiche, Università di Catania, I-95125 Catania, Italy; ³Department of Physiology and Pharmacology, University of Toledo, OH, USA

Received May 3, 2011; Accepted June 6, 2011

DOI: 10.3892/ijo.2011.1107

Abstract. Benign prostate hypertrophy (BPH) and prostate cancer (PC) are prostate chronic diseases that require a long period for development from a small lesion to clinical manifestation. PC is the most common cancer in men in Europe and the Americas. Tumor growth and metastasis depend upon the development of neovasculature around the tumor. This process, called angiogenesis, may be regulated by NO, and thus modulation of NO production could play an important role in tumor progression. Recent studies report the involvement of DDAH, an enzyme which metabolizes the endogenous NOS inhibitor ADMA, in the development of tumor vasculature. The aim of the present study was to verify the involvement of the DDAH/NOS pathway in the progression of prostate cancer. The effect of the NOS inhibitor L-NAME was evaluated in the human prostate cancer cell line LnCap and in BPH-1 cells which represent benign prostatic hypertrophy. Higher DDAH-2, eNOS, iNOS and VEGF expression was found in LnCap cells compared to BPH-1 cells. L-NAME treatment of LnCap cells resulted in a reduction in VEGF, iNOS and eNOS expression. VEGF, iNOS and eNOS inhibition is a promising approach for targeting tumor vasculature and certain NOS inhibitors could potentially serve as experimental agents for treatment of certain chemoresistant tumors, including prostate tumors. Moreover, since in our experimental conditions L-NAME was unable to reduce DDAH activity and expression, it is plausible to hypothesize the development of a targeted polypharmacological approach by developing dual and specific inhibitors of DDAH and NOS to better control NO biosynthesis.

Introduction

Benign prostate hypertrophy (BPH) and prostate cancer (PC) are prostate chronic diseases that require a long period for

development from a small lesion to clinical manifestation. PC is the second leading cause of death in men of Western world (1) (American Cancer Society 2007 Prostate Cancer Statistics- <http://www.cancer.org>; American Society of Clinical Oncology Prostate Cancer Statistics- <http://www.cancer.net/prostate>).

Despite significant improvements in local and systemic therapies, most deaths from prostate cancer are due to metastasis which resist conventional therapies (2-4). Therefore, novel therapeutic strategies targeting specific molecular markers are being pursued to allow early detection and cure.

Tumor growth and metastasis depend upon the development of a neovasculature around the tumor (5-9). This process, called angiogenesis, is critical to tumorigenicity and metastasis (10). Similarly to carcinogenesis, angiogenesis is a multistep process, regulated by a balance between stimulatory and inhibitory factors released by the tumor and its microenvironment (7,11-17).

Angiogenesis facilitates tumor growth through a series of steps including dissociation of endothelial cells (EC) from adjacent pericytes, remodelling of extracellular matrix, proliferation and migration of EC and capillary differentiation.

Nitric oxide (NO) is a signalling molecule produced by three isoforms of nitric oxide synthases (neuronal NOS, endothelial NOS and inducible NOS); it mediates a variety of actions such as vasodilatation, neurotransmission, host defence against bacteria and tumor cells (18,19).

Strong evidence suggests that NO is a regulator of angiogenesis (20,21), which enhances vascular permeability, induces extracellular matrix degradation, endothelial cell proliferation and migration (22-24) and stimulates the expression of vascular growth factor (VEGF) (25,26). Increased iNOS expression and NO production in BPH and in high grade PC occur when compared to normal tissue (27). Prostate cancer cells express lower levels of antioxidant enzymes than BPH cells and compared to normal prostatic cells, activity of antioxidant enzymes is decreased in BPH cells (28,29). Although conflicting data have been reported, an overwhelming amount of clinical and experimental evidence suggested a positive association between NO production and tumor progression (30-39). Modulation of NO production may therefore play an important role in regulation of angiogenesis and consequently in tumor progression. Overexpression of dimethylarginine dimethylaminohydrolase (DDAH), enzyme which metabolizes the endogenous NOS inhibitor asymmetric

Correspondence to: Professor Valeria Sorrenti, Dipartimento di Scienze del Farmaco, Sezione di Biochimica, Università di Catania, v.le A. Doria 6, I-95125 Catania, Italy
E-mail: sorrenti@unict.it

Key words: DDAH, NOS, VEGF, L-NAME, angiogenesis, prostate cancer

dimethylarginine (ADMA), reduces tissue ADMA levels and enhances angiogenesis (40).

The involvement of DDAH in cerebral tumor growth and the development of tumor vasculature has been reported (41). Two isoforms of DDAH have been identified: DDAH-1 and DDAH-2. Although there is some overlapping between the sites of expressions of DDAH-1 and nNOS (neuronal NOS) and between DDAH-2 and eNOS (endothelial NOS), it is now evident that both DDAHs are widely expressed and not confined to NOS expressing cells or tissues (42). Both isoforms have been identified in the prostate tissue, but the expression of DDAH-2 isoform appears more abundant (43).

In order to verify the involvement of DDAH/NOS pathway in the progression of prostate cancer, two different cell lines were used in the present study: BPH-1 cells which represent benign prostatic hypertrophy and LnCap, which are a model of human prostatic carcinoma (44,45). In addition, the effect of the NOS inhibitor *N*^G-nitro-L-arginine methyl ester (L-NAME), which is not degraded by DDAH (40), was examined.

Materials and methods

Cell culture conditions. Human prostate BPH-1 cells were purchased from Deutsche Sammlung Von Mikroorganism Und Zellkulturen-GmbH (DSMZ-GmbH) and grown in 80% RPMI-1640 medium supplemented with 20% fetal bovine serum (FBS) and 20 ng/ml testosterone, 5 µg/ml sodium selenite, 5 µg/ml insulin and a trace elements mix. Human prostate cancer LnCap cells were purchased from American Type Culture Collection (Manassas, VA) and grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 0.1% streptomycin-penicillin, 1% L-glutamine, 1% sodium pyruvate and 1% glucose. Cells were incubated at 37°C in a 5% CO₂ humidified atmosphere and maintained at subconfluency by passaging with trypsin-EDTA (Gibco).

Cell viability. To monitor cell viability, BPH-1 and LnCap cells were seeded 2x10⁵ cells per well in a 96-well, flat-bottomed 200 µl microplate. Cells were incubated at 37°C in a 5% CO₂ humidified atmosphere and cultured for either 24 or 72 h, in the presence and absence of different concentrations of L-NAME (0.1-1 mM). Four hours before the end of treatment, 20 µl of 0.5% 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in phosphate buffered saline (PBS) were added to each microwell. After incubation with the reagent, the supernatant was removed and replaced with 100 µl DMSO. The amount of formazan produced is proportional to the number of viable cells present. The optical density was measured using a microplate spectrophotometer reader (Thermo Labsystems Multiskan) at λ = 570 nm. Results are expressed as the percentage of formazan produced in treated cells with respect to untreated cells.

Cell count. Cell count was performed on 100 µl of cell suspension using a Burkner counting chamber divided into 16 fields of 1 mm². Sedimented cells present in 4 fields were counted. Arithmetical mean x 10⁴ represents the number of cells/ml of medium.

LDH release. Lactic dehydrogenase (LDH) activity was measured spectrophotometrically in the culture medium and cell lysates by analyzing the decrease in NADH absorbance at

λ = 340 nm during the pyruvate-lactate transformation, as previously reported (46,47). Cells were lysed with 50 mM Tris-HCl and 20 mM EDTA pH 7.4 plus 0.5% sodium dodecyl sulfate, further disrupted by sonication and centrifuged at 13,000 g for 15 min. The assay mixture (1 ml final volume) for the enzymatic analysis contained 33 µl of sample (5-10 µg of protein) in 48 mM PBS pH 7.5 plus 1 mM pyruvate and 0.2 mM NADH. The LDH released was calculated as percentage of the total amount, considered as the sum of the enzymatic activity present in the cell lysate and that in the culture medium. The optical density was measured using a Hitachi U-2000 dual beam spectrophotometer (Hitachi, Tokyo, Japan).

Western blotting. BPH-1 and LnCap cells cultured for 24 h, in both the presence and absence of 0.1-1 mM L-NAME, were suspended in 25 mM Tris buffer, pH 8.5, containing 100 mM NaCl (Sigma-Aldrich, St. Louis, MO, USA), 7 mM mercaptoethanol (Merck KGaA, Darmstadt, Germany) and a protease inhibitor cocktail (1:1000) (Sigma-Aldrich) and then sonicated for 3 cycles of 5 sec. The whole lysate was collected to evaluate DDAH-2, VEGF, eNOS and i-NOS expressions by Western blot analysis. Briefly, 50 µg of lysate was loaded in a 10% SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked with 3% fat-free milk in 10 mM Tris-HCl (pH 7.4), 150 mM NaCl and 0.05% TBST buffer, at 4°C for 2 h and then incubated with polyclonal anti-DDAH-2 (Calbiochem EMD Biosciences, Inc., Darmstadt, Germany), monoclonal anti-eNOS (Sigma-Aldrich), anti-VEGF (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) and anti-iNOS (Santa Cruz Biotechnologies) antibodies overnight at room temperature, with constant shaking. The same membranes were used for blotting with anti-β-actin (Santa Cruz Biotechnologies) antibody as an internal loading control. The filters were then washed and probed with horseradish peroxidase-conjugated donkey secondary anti-mouse, anti-rabbit and anti-goat IgG (Amersham Biosciences, Piscataway, NJ, USA) at a dilution of 1:5000. Chemiluminescence detection was performed with the ECL plus detection kit (Amersham) according to the manufacturer's instructions. Western blot analyses were quantified by densitometric analysis performed after normalization with β-actin. Results were expressed as arbitrary units (AU).

DDAH enzyme activity assay. Cell lysates were centrifuged at 2000 g for 45 min at 4°C and supernatants were collected for evaluating DDAH enzymatic activity and protein content by the Lowry *et al* assay (48). DDAH activity was assayed by determining L-citrulline formation in 96-well microtiter plate (49). One unit of enzyme activity was defined as the amount of enzyme catalyzing the formation of 1 µmol L-citrulline/min at 37°C.

NO₂/NO₃⁻ quantification. Nitrite, the stable metabolite of NO, was measured colorimetrically via Griess's reaction. Based on results regarding cell viability, for NO₂/NO₃⁻ determination, cells were cultured in presence or absence of 0.1-1 mM L-NAME for 24 h, after which the media were removed and used as below described.

Aliquots of cell culture medium (100 µl) were preincubated for 30 min at room temperature with 50 µM NADPH (Sigma-Aldrich) and 24 mU of nitrate reductase (Roche Diagnostics




Figure 1. Cell viability in cultured BPH-1 and LnCap cells after treatment with different L-NAME (0.1-1 mM) concentrations for 24 and 72 h. Values are the mean \pm SD of 4 experiments in triplicate. Significance of L-NAME (0.1-1 mM) versus BPH-1 control; ** $p < 0.005$. Significance of L-NAME (0.1-1 mM) versus LnCap control; * $p < 0.05$.

Gmbh, Mannheim, Germany). Samples were then treated with 0.2 U of lactate dehydrogenase (Roche Diagnostics Gmbh) and 0.5 μ mol of sodium pyruvate for 10 min. The coloration was developed adding Griess reagent (Merck KGaA) (1:1, v/v). Finally, after 10 min at room temperature, absorbance was recorded using a 96-well plate microtiter (Thermo Labsystems Multiskan) at $\lambda = 540$ nm. Nitrite levels were determined using a standard curve and expressed as nmoles of $\text{NO}_2^-/\text{NO}_3^-/1 \times 10^6$ cells.

Statistical analyses. The data are presented as means \pm SD for 4 experiments in triplicate. One-way variance analysis and Student's t-test were used where appropriate; $p < 0.05$ was regarded as significant.

Results

Effect of L-NAME on BPH-1 and LnCap cell proliferation. Cell viability, measured as functionality of succinate dehydrogenase, is reported in Fig. 1. The exposition of cell culture to 0.1 mM L-NAME did not modify BPH-1 and LnCap viability after either 24 or 72 h. When BPH1 and LnCap cells were exposed to 1 mM L-NAME, a significant reduction in viability was observed. This effect was less in LnCap cells when compared to BPH-1 cells and was not time-dependent since both 24 and 72 h of exposure to L-NAME elicited the same 30 or 40% reduction in cell viability. The growth of BPH-1 and LnCap cell lines was examined by direct cell counting after treatment for 72 h with L-NAME (0.1 and 1 mM) (Fig. 2). Although the results obtained show a reduction in cell number after 72 h of exposure to L-NAME, LnCap cells appeared more resistant to L-NAME treatment compared to BPH-1 cells. In fact, a significant cell number reduction was evident only at 1 mM concentration (Fig. 2A). Fig. 2B shows representative images of BPH-1 and LnCap cells cultured in the presence and absence of 1 mM L-NAME and show a significant decrease in cell number. The results of LDH release after exposure to L-NAME are shown in Fig. 3. Twenty-four-hour exposure to 0.1 mM L-NAME did not increase LDH release in either BPH-1 or LnCap. However both cell types showed increased LDH release, particularly after 72 h of treatment with 1 mM L-NAME ($p < 0.005$).




Figure 2. Cell count in BPH-1 and LnCap cells after treatment with different L-NAME (0.1-1 mM) concentrations for 72 h. Values are mean \pm SD of 4 experiments in triplicate (A). Significance of 1 mM L-NAME versus BPH-1 control; ** $p < 0.005$. Significance of 1 mM L-NAME versus LnCap control; * $p < 0.05$. (B) Representative images of BPH-1 and LnCap cells cultured in presence and absence of 1 mM L-NAME treatment.




Figure 3. Percentage of LDH released in culture medium of BPH-1 and LnCap cells after treatment with different L-NAME (0.1-1 mM) concentrations for 24 and 72 h. Values are the mean \pm SD of 4 experiments in triplicate. Significance of 1 mM L-NAME versus control; * $p < 0.05$.

Effect of L-NAME on DDAH-2, eNOS, iNOS and VEGF expression in LnCap cells and BPH-1 cells. Higher DDAH-2 expression




Figure 4. Effect of L-NAME (0.1-1 mM) on DDAH-2 expression in cultured BPH-1 and LnCap cells. Results, expressed as arbitrary units (AU), represent the mean \pm SD of 4 experiments (A). Significance of 0.1 mM L-NAME versus BPH-1 control (C); ** $p < 0.005$. Significance of 1 mM L-NAME versus BPH-1 control and of L-NAME (0.1-1 mM) versus LnCap control (C); * $p < 0.05$. (B) Representative Western blotting of DDAH-2 protein expression in cultured BPH-1 and LnCap cells.

was found in LnCap cells compared to BPH-1 cells. L-NAME treatment resulted in an increase in DDAH-2 in both BPH-1 and LnCap cells. However the effects were different. In BPH-1 0.1 mM L-NAME increased DDAH-2 expression ($p < 0.005$) to a greater extent than 1 mM L-NAME. In LnCap cells both 0.1 and 1 mM L-NAME increased DDAH-2 expression to the same extent ($p < 0.05$) (Fig. 4A). Fig. 4B reports representative Western blotting of DDAH-2 protein expression in cultured BPH-1 and LnCap cells. Higher eNOS expression was found in LnCap cells compared to BPH-1 cells. L-NAME had no effect in eNOS expression in BPH-1 cells. In contrast L-NAME (0.1 and 1 mM) produced a significant dose-dependent decrease ($p < 0.005$) in eNOS expression in LnCap cells (Fig. 5A). Fig. 5B reports representative Western blotting of eNOS protein expression in cultured BPH-1 and LnCap cells. Higher iNOS expression was found in LnCap cells compared to BPH-1 cells. L-NAME had no effect in iNOS expression in BPH-1 cells. In contrast L-NAME produced a significant dose-dependent decrease in iNOS expression in LnCap cells (Fig. 6A). Fig. 6B reports representative Western blotting of iNOS protein expression in cultured BPH-1 and




Figure 5. Effect of L-NAME (0.1-1 mM) on eNOS expression in cultured BPH-1 and LnCap cells. Results, expressed as arbitrary units (AU), represent the mean \pm SD of 4 experiments (A). Significance of L-NAME (0.1-1 mM) versus control (C); * $p < 0.005$. (B) Representative Western blotting of eNOS protein expression in cultured BPH-1 and LnCap cells.

LnCap cells. Higher VEGF expression was found in LnCap cells compared to BPH-1 cells. L-NAME had no effect on VEGF expression in BPH-1 cells. VEGF expression was unaffected by 0.1 mM L-NAME in Ln Cap cells, however 1 mM L-NAME produced a significant ($p < 0.005$) decrease in VEGF expression (Fig. 7A). Fig. 7B reports representative Western blotting of VEGF protein expression in cultured BPH-1 and LnCap cells.

Effect of L-NAME on DDAH activity. L-NAME resulted in a significant ($p < 0.05$) increase in DDAH activity at both 0.1 and 1 mM L-NAME in BPH-1 cells. Control levels of DDAH activity were higher in LnCap cells when compared to BPH-1 cells. L-NAME resulted in a dose-dependent increase in DDAH activity ($p < 0.005$) when compared to control in LnCap cells (Fig. 8).

Effect of L-NAME on nitrite/nitrate levels. The effect of both concentrations, 0.1 and 1 mM, of L-NAME was examined in BPH-1 and LnCap cells. The dose of 0.1 mM L-NAME had no effect on nitrite/nitrate levels in either cell line. In contrast, 1 mM L-NAME caused a significant ($p < 0.05$) decrease in nitrite/nitrate levels in both cell lines (Table I).




Figure 6. Effect of L-NAME (0.1-1 mM) on iNOS expression in cultured BPH-1 and LnCap cells. Results, expressed as arbitrary units (AU), represent the mean \pm SD of 4 experiments (A). Significance of L-NAME (0.1 mM) versus control (C); * p <0.05. Significance of L-NAME (1 mM) versus control (C); ** p <0.005. (B) Representative Western blotting of iNOS protein expression in cultured BPH-1 and LnCap cells.




Figure 7. Effect of L-NAME (0.1-1 mM) on VEGF expression in cultured BPH-1 and LnCap cells. Results, expressed as arbitrary units (AU), represent the mean \pm SD of 4 experiments (A). Significance of L-NAME (1 mM) versus control (C); * p <0.005. (B) Representative Western blotting of VEGF protein expression in cultured BPH-1 and LnCap cells.

Table I. Nitrite/nitrate levels in BPH-1 and LnCap cells.

| Nitrite/nitrate | | nmoles/ 1×10^6 cells |
|-----------------|---------------|-------------------------------|
| BPH-1 | Control | 25.26 \pm 0.5 |
| | L-NAME 0.1 mM | 24.66 \pm 0.7 |
| | L-NAME 1 mM | 18.07 \pm 0.3 ^a |
| LnCap | Control | 38.25 \pm 1.9 |
| | L-NAME 0.1 mM | 37.65 \pm 1.3 |
| | L-NAME 1 mM | 21.66 \pm 1.1 ^a |

Results represent the mean \pm SD of four experiments. Significance of 1 mM L-NAME versus control. ^a p <0.05.

Discussion

Angiogenesis is a multi-step process that may be considered a major factor affecting the metastatic spread of malignant cells (50,51). Investigations published on experimental tumor models and on several types of human tumor including gynecologic, head and neck, breast, central nervous system, colorectal and




Figure 8. Effect of different L-NAME (0.1-1 mM) concentrations on DDAH activity in cell lysates. Enzymatic activity was determined by measuring L-citrulline formation and expressed as nmoles/mg of protein/min. Results represent the mean \pm SD of 4 experiments. Significance of LnCap control versus BPH-1 control: * p <0.005. Significance of L-NAME (0.1-1 mM) versus BPH-1 control; § p <0.05. Significance of L-NAME (0.1-1 mM) versus LnCap control; ** p <0.005.

prostate cancer (32,33,35,39,52-58) have shown an increased expression of iNOS. Such overexpression has been correlated to




Figure 9. DDAH/NOS pathway: effect of NOS inhibitor L-NAME.

tumor progression. In addition eNOS overexpression has been reported in various type of cancer including prostate cancer (37,59-64). NO produced by eNOS may be involved in tumor angiogenesis. On the other hand, it has been shown that in the absence of eNOS tumor cells became more dependent on iNOS-derived NO for survival and tumor angiogenesis (65). Therefore, NO produced by iNOS may contribute to tumor angiogenesis. The significant decrease in BPH-1 and LnCap cell number with 1 mM L-NAME treatment that we report, is in agreement with increased LDH release. We show that cell survival was decreased after L-NAME treatment under our experimental conditions. However, tumoral LnCap cells are more resistant to treatment when compared to BPH1 cells. Moreover, the reduction in BPH-1 cell survival induced by L-NAME may represent a preventive strategy because patients with BPH would be stratified as cases at higher risk of carcinogenic development in the prostate (66).

The increased iNOS and eNOS expression that we report, support the hypothesis that NOS overexpression in prostatic cancer cells, as in numerous other cancer cell lines, may be correlated with tumor progression and metastasis (30-35,37,39,54,62,67). In addition, increased eNOS, iNOS and VEGF expressions, could contribute to tumor progression by enhancing tumor vascularization (65,68,69). The resistance of LnCap cells to L-NAME treatment may be related to iNOS and eNOS overexpression, in fact iNOS and eNOS overexpression has been correlated with aggressive tumor phenotype and poor prognosis (55,70). Moreover, results obtained in the present study suggest that also in prostate cancer, as in cerebral tumors (41), increased expression and activity of DDAH-2 may contribute to stimulating tumor growth and angiogenesis through increased NO formation.

Targeting angiogenesis in the therapeutic intervention of cancer has received substantial attention. In particular, therapeutic interventions using molecules that may modulate the DDAH/NOS pathway are plausible. NOS inhibitors have been suggested as antitumor therapeutics (52,65,69,71-81). However, the antitumor and antimetastatic effects of NOS inhibitors may be attributed in part to reduced tumor cell invasiveness (52,72,73,78,81) and in part to reduced neovascularization (69,71,74,75,77,79). The importance of the DDAH/NOS pathway in the angiogenic process is confirmed by treatment with the NOS inhibitor L-NAME, which, under our experimental conditions, resulted in a reduction, not only in iNOS and eNOS activity, but also in VEGF, iNOS and eNOS expression. These effects may explain a possible antiangiogenic effect of L-NAME (82,83) and are in agreement with studies that show angiogenesis inhibition in DDAH-TG mice by exogenous L-NAME (40).

The increased DDAH-2 expression and activity reported after L-NAME treatment, both of BPH-1 and LnCap cells, may represent an adaptational response to the presence of L-NAME (an inhibitor that is not degraded by DDAH) by reducing endogenous ADMA levels. iNOS and eNOS inhibition is a promising approach for targeting tumor vasculature and certain NOS inhibitors potentially serve as experimental agents for treatment of certain chemoresistant tumors, including prostate tumors (Fig. 9). Moreover, since L-NAME was unable to reduce DDAH activity and expression, as reported by Wang *et al* (84), it is plausible to hypothesize the development of a targeted polypharmacological approach by developing dual and specific inhibitors of DDAH and NOS to better control NO biosynthesis.

References

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 46: 765-781, 2010.
2. Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P and Tuli S: Predictors of survival in patients with prostate cancer and spinal metastasis. *J Neurosurg Spine* 13: 789-794, 2010.
3. Nayyar R, Sharma N and Gupta NP: Prognostic factors affecting progression and survival in metastatic prostate cancer. *Urol Int* 84: 159-163, 2010.
4. Yigitbasi O, Ozturk U, Goktug HN, Gucuk A and Bakirtas H: Prognostic factors in metastatic prostate cancer. *Urol Oncol* 29: 162-165, 2011.
5. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. *Cancer Res* 46: 467-473, 1986.
6. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* 339: 58-56, 1989.
7. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. *Cell* 64: 327-336, 1999.
8. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. *Cell* 79: 185-188, 1994.
9. Folkman J: Clinical applications of research on angiogenesis. *N Engl J Med* 333: 1757-1763, 1995.
10. Hanahan D and Weinberg RA: The hallmarks of cancer. *Cell* 100: 57-70, 2000.
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? *J Nat Cancer Inst* 82: 4-6, 1990.
12. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. *Nature* 438: 967-974, 2005.
13. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC and Harris AL: Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvascular density, Chalkeley count, and computer image analysis. *J Pathol* 177: 275-283, 1995.
14. Weidner N, Carroll P, Flax J, Blumenfeld W and Folkman J: Tumour angiogenesis: correlation with metastases in invasive prostate carcinoma. *Am J Pathol* 143: 401-409, 1993.
15. Brustman H, Riss P and Naude S: The relevance of angiogenesis in benign and malignant epithelial tumours of the ovary: a quantitative histological study. *Gynecol Oncol* 67: 20-26, 1997.
16. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 86: 353-364, 1996.
17. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1: 23-31, 1995.
18. Moncada S, Palmer RMJ and Higgs EA: Nitric oxide: physiology, pathology and pharmacology. *Pharm Rev* 43: 109-142, 1991.
19. Xu W, Liu LZ, Loizidou M, Ahmed M and Charles IG: The role of nitric oxide in cancer. *Cell Res* 2: 311-320, 2002.
20. Chinje EC and Stratford IJ: Role of nitric oxide in growth of solid tumours: a balancing act. *Essays Biochem* 32: 61-72, 1997.
21. Griffioen AW and Molema G: Angiogenesis: potentials or pharmacologic intervention in the treatment of cancer, cardiovascular disease and chronic inflammation. *Pharm Rev* 52: 237-268, 2000.

22. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P and Ledda F: Nitric oxide mediates angiogenesis *in vivo* and endothelial cell growth and migration *in vitro* promoted by substance. *PJ Clin Invest* 94: 2036-2044, 1994.
23. Trachtman H, Futterweit S, Garg P, Reddy K and Singhal PC: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesengial cells. *Biochem Biophys Res Commun* 218: 704-708, 1996.
24. Fukumura D, Yuan F, Endo M and Jain RK: Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. *Am J Pathol* 150: 713-725, 1997.
25. Chin K, Kurashima Y, Ogura T, Tajiri H, Yoshida S and Esumi H: Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. *Oncogene* 15: 437-442, 1997.
26. Papapetropoulos A, Garcia-Cardena G, Madri JA and Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cell. *J Clin Invest* 100: 3131-3139, 1997.
27. Sciarra A, Mariotti G, Saliciccia S, Gomez AA, Monti S, Toscano V and Di Silverio F: Prostate growth and inflammation. *J Steroid Biochem Mol Biol* 108: 254-260, 2008.
28. Aydin A, Arsofa-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, Ozgok Y and Dimovski A: Oxidative stress and anti-oxidant in non-metastatic prostate cancer and benign prostatic hyperplasia. *Clin Biochem* 39: 176-179, 2006.
29. Jung K, Seidel B, Rudolph B, Lein M, Cronauer MV, Henke W, Hampel G, Schnorr D and Loening SA: Antioxidant enzymes in malignant cell lines and in primary cultured prostatic cells. *Free Radical Biol Med* 23: 127-133, 2007.
30. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V and Moncada S: Nitric oxide synthase activity in human gynecological cancer. *Cancer Res* 54: 1352- 1354, 1994.
31. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity in human breast cancer. *Br J Cancer* 72: 41-44, 1995.
32. Duenas-Gonzalez A, Isales CM, del Mar Abad-Hernandez M, Gonzalez-Sarmiento R, Sanguenza O and Rodriguez-Commes J: Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. *Mol Pathol* 10: 645-649, 1997.
33. Cobbs CS, Brennan JE, Aldape KD, Bredt DS and Israel MA: Expression of nitric oxide synthase in human central nervous system tumors. *Cancer Res* 55: 727-730, 1995.
34. Thomsen LL and Miles DW: Role of nitric oxide in tumor progression: lessons from human tumors. *Cancer Metastasis Rev* 17: 107-118, 1998.
35. Klots T, Bloch W, Volberg C, Engelmann U and Addicks K: Selective expression of inducible nitric oxide synthase in human prostate carcinoma. *Cancer* 82: 1897-1903, 1998.
36. Chen GG, Lee TW, Xu H, Yip JH, Li M, Mok TS and Yim AP: Increased inducible nitric oxide synthase in lung carcinoma of smokers. *Cancer* 112: 372-381, 2008.
37. Lukes P, Pàcovà H, Kucera T, Vesely D, Martinek J and Asti J: Expression of endothelial and inducible nitric oxide synthase and caspase-3 in tonsillar cancer, chronic tonsillitis and healthy tonsils. *Folia Biol* 54: 141-145, 2008.
38. Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV and Langdon JD: Type II nitric oxide synthase (NOS₂) expression correlates with lymphnode status in oral squamous carcinoma. *J Oral Pathol Med* 30: 129-134, 2001.
39. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. *J Natl Cancer Inst* 90: 587-596, 1998.
40. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM and Cooke JP: Overexpression of dimethyl arginine dimethylamino hydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. *Circulation* 22: 1431-1438, 2005.
41. Kostourou V, Robinson SP, Cartwright JE and Whitley GS: Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. *Br J Cancer* 87: 673-680, 2002.
42. Leiper J, Santa Maria J, Chubb A, MacAllister RJ, Charles I, Whitley GSJ and Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to microbial arginine deiminases. *Biochem J* 343: 209-214, 1999.
43. Tran CT, Fox MF, Vallance P and Leiper JM: Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. *Genomics* 68: 101-105, 2000.
44. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LnCap model of human prostatic carcinoma. *Cancer Res* 43: 1809-1818, 1983.
45. Hayward SW, Dahiya R, Cunha G R, Bartek J, Deshpande N and Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH1. *In Vitro Cell Dev Biol* 31A: 14-24, 1995.
46. Pavone A and Cardile V: An *in vitro* study of new antiepileptic drugs and astrocytes. *Epilepsia* 44 (Suppl 10): 34-39, 2003.
47. Renis M, Cardile V, Grasso S, Palumbo M and Scifo C: Switching off HSP70 and i-NOS to study their role in normal and H₂O₂-stressed human fibroblasts. *Life Sci* 74: 757-769, 2003.
48. Lowry OH, Rosenbrough NJ, Farr AJ and Randall RG: Protein measurement with the Folin phenol reagent. *J Biol Chem* 193: 265-275, 1951.
49. Knipp M and Vasak M: A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline. *Anal Biochem* 286: 257-264, 2000.
50. Liekens S, De Clercq E and Neyts J: Angiogenesis: regulators and clinical application. *Biochem Pharmacol* 61: 253-270, 2000.
51. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A and Matsuyama K: Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. *Cancer Res* 57: 1043-1046, 1997.
52. Orlucevic A, Bechberger J, Green A M, Shapiro RA, Billiar TR and Lala PK: Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. *Int J Cancer* 81: 889-896, 1999.
53. Svec J, Ergang P, Mandys V, Kment M and Pácha J: Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models. *Int J Exp Pathol* 91: 44-53, 2010.
54. Saed GM, Ali-Fehmi R, Jiang ZL, Fletcher NM, Diamond MP, Abu-Soud HM and Munkarah MR: Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. *Gynecol Oncol* 116: 276-281, 2010.
55. Lecuru F, Metzger U, Levy E, Lefrere-Belda MA and Bensaid C: Ovarian cancer: diagnosis of early stages, referral of patients and management. *Rev Prat* 54: 1763-1769, 2004.
56. Wang YZ, Cao YQ, Wu JN, Chen M and Cha XY: Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. *World J Gastroenterol* 11: 46-50, 2005.
57. Peng JP, Zheng S, Xiao ZX and Zhang SZ: Inducible nitric oxide synthase expression is related to angiogenesis, bcl-2, and cell proliferation in hepatocellular carcinoma. *J Zhejiang Univ Sci* 4: 221-227, 2003.
58. Narayanan BA, Narayanan NK, Simi B and Reddy BS: Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. *Cancer Res* 63: 972-979, 2003.
59. Lim KH, Ancrile BB, Kashatus DF and Counter CM: Tumour maintenance is mediated by eNOS. *Nature* 452: 646-649, 2008.
60. Fukumura D, Kashiwagi S and Jain RK: The role of nitric oxide in tumor progression. *Nat Rev Cancer* 6: 521-534, 2006.
61. Ying L and Hofseth LJ: An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. *Cancer Res* 67: 1407-1410, 2007.
62. Polytaichou C, Hatziaepostolou M, Poimenidi E, Papadopoulou A, Parthymou A and Papadimitriou E: Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphate beta/zeta. *Int J Cancer* 124: 1785-1793, 2009.
63. Shang ZJ and Li JR: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression. *J Oral Pathol Med* 34: 134-139, 2005.
64. Bentz BG, Haines GK, Lingen MW, Pelzer HJ, Hanson DG and Radosevich JA: Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. *Am Otol Rhinol Laryngol* 108: 781-787, 1999.
65. Chen G, Qian HS, Liu P, Brooks A, Rubanyi GM and Kausar K: i-NOS derived NO substitutes for endothelial NO in tumor angiogenesis and tumor growth in the absence of eNOS expression. *Nitric Oxide* 14: A16, 2006.

66. Hamid ARAH, Umbas R and Mochtar CA: Recent role of inflammation in prostate diseases: chemoprevention development opportunity: Acta Med Indones-Indones. J Intern Med 43: 59-65, 2011.
67. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga, M and Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Inst 88: 1190-1198, 1997.
68. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk Huang DJ and Jain RK: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98: 2604-2609, 2001.
69. Malone JM, Saed GM, Diamond MP, Sokol RJ and Munkaraha AR: The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am J Obstet Gynecol 194: 1110-1118, 2006.
70. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolose M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M and Farsetti A: Endothelial NOS, estrogen receptor β , and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119: 1093-1108, 2009.
71. Tozer GM, Prise VE, Lewis G, Xie S, Wilson I and Hill SA: Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects oombretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 15: 3781-3790, 2009.
72. Punathil T, Tollefsbol TO and Katiyar SK: EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. Biochem Biophys Res Commun 375: 162-167, 2008.
73. Yu LB, Dong XS, Sun WZ, Zhao DL and Yang Y: Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. World J Gastroenterol 11: 6385-6388, 2005.
74. Kon K, Fujii S, Kosaka H and Fujiwara T: Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester retards vascular sprouting in angiogenesis. Microvasc Res 65: 2-8, 2003.
75. Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ and Ellis LM: Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an *in vivo* model of pancreatic cancer. Clin Cancer Res 12: 2628-2633, 2006.
76. Pullen NA and Fillmore HL: Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. J Neurooncol 96: 201-209, 2010.
77. Uneda S, Hata H, Matsuno F, Nagasaki A, Harada N, Mitsuya Y, Matsuzaki H and Mitsuya H: A nitric oxide synthase inhibitor, N(G)-nitro-L-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br J Haematol 120: 396-404, 2003.
78. Punathil T and Katiyar SK: Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2. Mol Carcinog 48: 232-242, 2009.
79. Thejass P and Kuttan G: Allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC) inhibit tumour-specific angiogenesis by downregulating nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) production. Nitric Oxide 16: 247-257, 2007.
80. Fitzpatrick B, Mehibel M, Cowen RL and Stratford IJ: iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19: 217-224, 2008.
81. Ohtsu N, Takaoka K, Segawa E, Hashitani S, Noguchi K, Kishimoto H and Urade M: Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. Oncol Rep 24: 31-36, 2010.
82. Jadeski LC and Lala PK: Nitric oxide synthase inhibition by NG-Nitro-L-Arginine methyl ester inhibits tumor induced angiogenesis in mammary tumors. Am J Pathol 155: 1381-1390, 1999.
83. Davel L, Eijan AM, Sales ME, Espanol A, D'Agostino A, Piccardo I, Lauria L, De Lustig ES and Jasnis MA: Reactivity of tumor-draining lymph nodes and the nitric oxide pathway. Int J Oncol 20: 59-67, 2002.
84. Wang Y, Monzingo AF, Hu S, Schaller TH, Robertus JD and Fast W: Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochemistry 48: 8624-8635, 2009.